HDAC9 and mantle cell lymphoma: Among the 152 patients with MCL who experienced any type of anti-cancer therapy, 136 (89.5%) received induction immunochemotherapy with (R)-CHOP-like (N = 70) or with regimens based on (R)-HDAC (N = 66).